Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein

British Journal of Pharmacology

Volumn 162, Issue 3, 2011, Pages 773-784

  Kim, Ju Hwa ^a   Chae, Minji ^a   Kim, Won Ki ^a   Kim, You Jin ^a   Kang, Han Sung ^a   Kim, Hyung Sik ^b   Yoon, Sungpil ^a  

^a National Cancer Center   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

DNA damage; doxorubicin; etoposide; p21; salinomycin

Indexed keywords

BRCA1 PROTEIN; CHECKPOINT KINASE 1; CYCLIN D1; DOXORUBICIN; ETOPOSIDE; HISTONE H2AX; P53 BINDING PROTEIN 1; PROTEIN P21; PROTEIN P53; SALINOMYCIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL STRAIN HEPG2; CELL STRAIN MCF 7; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMET ASSAY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HEP G2 CELLS; HUMANS; IN SITU NICK-END LABELING; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRANS; SARCOMA; UTERINE NEOPLASMS;

EID: 78651445624     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01089.x     Document Type: Article

References (41)

1. Abukhdeir AM, Park BH, (2008). P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 10: e19.
2. Bidwell GL 3rd, Raucher D, (2006). Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem Pharmacol 71: 248-256.
3. Biganzoli L, Minisini A, Aapro M, Di Leo A, (2004). Chemotherapy for metastatic breast cancer. Curr Opin Obstet Gynecol 16: 37-41.
4. Chakraborty P, Sk UH, Bhattacharya S, (2009). Chemoprotection and enhancement of cancer chemotherapeutic efficacy of cyclophosphamide in mice bearing Ehrlich ascites carcinoma by diphenylmethyl selenocyanate. Cancer Chemother Pharmacol 64: 971-980.
5. Chetty C, Bhoopathi P, Lakka SS, Rao JS, (2007). MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line. Oncogene 26: 7675-7783.
6. Crivellari D, Aapro M, Leonard R, von Minckwitz G, Brain E, Goldhirsch A, et al. (2007). Breast cancer in the elderly. J Clin Oncol 25: 1882-1890.
7. Danson S, Dean E, Dive C, Ranson M, (2007). IAPs as a target for anticancer therapy. Curr Cancer Drug Targets 7: 785-794.
8. Devlin HL, Mack PC, Burich RA, Gumerlock PH, Kung HJ, Mudryj M, et al. (2008). Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol Cancer Res 6: 808-818.
9. Dillman RO, Barth NM, VanderMolen LA, Allen K, Beutel LD, Chico S, (2005). High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants. Am J Clin Oncol 28: 281-288.
10. Fang Y, Sullivan R, Graham CH, (2007). Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. Exp Cell Res 313: 867-877.
11. Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C, (2009). Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun 390: 743-749.
12. Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C, (2010). Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun 394: 1098-1104.
13. Glück S, (2005). Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. Oncologist 10: 780-791.
14. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659.
15. Hsiao CJ, Li TK, Chan YL, Hsin LW, Liao CH, Lee CH, et al. (2008). WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase ? inhibition and apoptotic machinery in prostate cancers. Biochem Pharmacol 75: 847-856.
16. Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, et al. (2007). Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 18: 409-420.
17. Hwang MN, Ha TH, Park J, Shim J, Lee H, Kim YN, et al. (2007). Increased SOCS6 stability with PMA requires its N-terminal region and the Erk pathway via Pkcdelta activation. Biochem Biophys Res Commun 354: 184-189.
18. Idogawa M, Sasaki Y, Suzuki H, Mita H, Imai K, Shinomura Y, et al. (2009). A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells. Clin Cancer Res 15: 3725-3732.
19. Inskip PD, Robison LL, Stovall M, Smith SA, Hammond S, Mertens AC, et al. (2009). Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 27: 3901-3907.
20. Kaklamani VG, Gradishar WJ, (2005). Adjuvant therapy of breast cancer. Cancer Invest 23: 548-560.
21. Kawabe T, (2004). G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3: 513-519.
22. Kim JH, Kim TH, Kang HS, Ro J, Kim HS, Yoon S, (2009). SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin. Biochem Biophys Res Commun 387: 450-455.
23. Kim JH, Lee SC, Ro J, Kang HS, Kim HS, Yoon S, (2010). Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines. Biochem Pharmacol 79: 373-380.
24. Lee EW, Lee MS, Camus S, Ghim J, Yang MR, Oh W, et al. (2009). Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J 28: 2100-2113.
25. Llovet JM, (2005). Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40: 225-235.
26. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, et al. (2007). Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 10: 13-29.
27. Mahmoudi N, de Julián-Ortiz JV, Ciceron L, Gálvez J, Mazier D, Danis M, (2006). Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening. J Antimicrob Chemother 57: 489-497.
28. Malumbres M, Barbacid M, (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166.
29. Mita AC, Mita MM, Nawrocki ST, Giles FJ, (2008). Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005.
30. Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O, Hirsoe C, (1974). Salinomycin, a new polyether antibiotic. J Antibiot 27: 814-821.
31. Nitiss JL, (2002). DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Curr Opin Investig Drugs 3: 1512-1516.
32. Park SH, Wang X, Liu R, Lam KS, Weiss RH, (2008). High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers. Cancer Biol Ther 7: 2015-2022.
33. Radhakrishnan SK, Bhat UG, Halasi M, Gartel AL, (2008). P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents. Oncogene 27: 1306-1309.
34. Riccioni R, Dupuis ML, Bernabei M, Petrucci E, Pasquini L, Mariani G, et al. (2010). The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis 45: 86-92.
35. Sherr CJ, McCormick F, (2002). The RB and p53 pathways in cancer. Cancer Cell 2: 103-112.
36. Solier S, Sordet O, Kohn KW, Pommier Y, (2009). Death receptor-induced activation of the Chk2-and histone H2AX-associated DNA damage response pathways. Mol Cell Biol 29: 68-82.
37. Thomadaki H, Scorilas A, (2008). Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol. Biol Chem 389: 1427-1434.
38. Van Valen F, Fulda S, Schäfer KL, Truckenbrod B, Hotfilder M, Poremba C, et al. (2003). Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer 107: 929-940.
39. Wang Y, Arriaga EA, (2008). Monitoring incorporation, transformation and subcellular distribution of N-l-leucyl-doxorubicin in uterine sarcoma cells using capillary electrophoretic techniques. Cancer Lett 262: 123-132.
40. Weiss RH, (2003). p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4: 425-429.
41. Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, et al. (2004). A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 103: 4659-4665.